|
1
|
Schiffer CA: BCR-ABl tyrosine kinase
inhibitors for chronic myelogenous leukemia. N Engl J Med.
357:258–265. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Carella AM, Branford S, Deininger M, et
al: What challenges remain in chronic myeloid leukemia research?
Haematologica. 98:1168–1172. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Pfeifer H, Wassmann B, Hofmann WK, et al:
Risk and prognosis of central nervous system leukemia in patients
with Philadelphia chromosome-positive acute leukemias treated with
imatinib mesylate. Clin Cancer Res. 9:4674–4681. 2003.PubMed/NCBI
|
|
4
|
Leis JF, Stepan DE, Curtin PT, et al:
Central nervous system failure in patients with chronic myelogenous
leukemia lymphoid blast crisis and Philadelphia chromosome positive
acute lymphoblastic leukemia treated with imatinib (STI-571). Leuk
Lymphoma. 45:695–698. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Wolff NC, Richardson JA, Egorin M and
Ilaria RL Jr: The CNS is a sanctuary for leukemic cells in mice
receiving imatinib mesylate for Bcr/Abl-induced leukemia. Blood.
101:5010–5013. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Petzer AL, Gunsilius E, Hayes M, et al:
Low concentrations of STI571 in the cerebrospinal fluid: a case
report. Br J Haematol. 117:623–625. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Bornhauser M, Jenke A, Freiberg-Richter J,
et al: CNS blast crisis of chronic myelogenous leukemia in a
patient with a major cytogenetic response in bone marrow associated
with low levels of imatinib mesylate and its N-desmethylated
metabolite in cerebral spinal fluid. Ann Hematol. 83:401–402. 2004.
View Article : Google Scholar
|
|
8
|
Dai H, Marbach P, Lemaire M, Hayes M and
Elmquist WF: Distribution of STI-571 to the brain is limited by
p-glycoprotein-mediated efflux. J Pharmacol Exp Ther.
304:1085–1092. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Bujassoum S, Rifkind J and Lipton JH:
Isolated central nervous system relapse in lymphoid blast crisis
chronic myeloid leukemia and acute lymphoblastic leukemia in
patients on imatinib therapy. Leuk Lymphoma. 45:401–403. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Isobe Y, Sugimoto K, Masuda A, Hamano Y
and Oshimi K: Central nervous system is a sanctuary site for
chronic myelogenous leukaemia treated with imatinib mesylate.
Intern Med J. 39:408–411. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Hochhaus A, Kantarjian HM, Baccarani M, et
al: Dasatinib induces notable hematologic and cytogenetic responses
in chronic-phase chronic myeloid leukemia after failure of imatinib
therapy. Blood. 109:2303–2309. 2007. View Article : Google Scholar
|
|
12
|
Kantarjian HM, Giles F, Gattermann N, et
al: Nilotinib (formerly AMN107), a highly selective BCR-ABL
tyrosine kinase inhibitor, is effective in patients with
Philadelphia chromosome-positive chronic myelogenous leukemia in
chronic phase following imatinib resistance and intolerance. Blood.
110:3540–3546. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Kantarjian H, Shah NP, Hochhaus A, et al:
Dasatinib versus imatinib in newly diagnosed chronic-phase chronic
myeloid leukemia. N Engl J Med. 362:2260–2270. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Saglio G, Kim DW, Issaragrisil S, et al:
Nilotinib versus imatinib for newly diagnosed chronic myeloid
leukemia. N Engl J Med. 362:2251–2259. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Porkka K, Koskenvesa P, Lundan T, et al:
Dasatinib crosses the blood-brain barrier and is an efficient
therapy for central nervous system Philadelphia chromosome-positive
leukemia. Blood. 112:1005–1012. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Abdelhalim A, Barcos M, Block AW, et al:
Remission of Philadelphia chromosome-positive central nervous
system leukemia after dasatinib therapy. Leuk Lymphoma.
48:1053–1056. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Alimena G, Breccia M, Latagliata R, et al:
Dasatinib in the management of lymphoid blast crisis of
Philadelphia-positive chronic myeloid leukemia with multiple
extra-medullary and intracranial localizations. Leuk Res.
33:e134–e136. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Nishimoto M, Nakamae H, Koh KR, et al:
Dasatinib maintenance therapy after allogeneic hematopoietic stem
cell transplantation for an isolated central nervous system blast
crisis in chronic myelogenous leukemia. Acta Haematol. 130:111–114.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Gutierrez-Aguirre H, Garcia-Rodriguez F,
Cantu-Rodriguez O, Gonzalez-Llano O, Jaime-Perez J and
Gomez-Almaguer D: Effectiveness of dasatinib in relapsed CNS, Ph+
ALL that is refractory to radiochemotherapy plus imatinib: a case
report. Clin Adv Hematol Oncol. 9:875–878. 2011.
|
|
20
|
Papageorgiou SG, Pappa V, Economopoulou C,
et al: Dasatinib induces long-term remission in imatinib-resistant
Philadelphia chromosome-positive acute megakaryoblastic leukemia
but fails to prevent development of central nervous system
progression. Leuk Res. 34:e254–e256. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Frigeri F, Arcamone M, Luciano L, Di
Francia R, Pane F and Pinto A: Systemic dasatinib fails to prevent
development of central nervous system progression in a patient with
BCR-ABL unmutated Philadelphia chromosome-positive leukemia. Blood.
113:5028–5029. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Cortes J: Central nervous system
involvement in adult acute lymphocytic leukemia. Hematol Oncol Clin
North Am. 15:145–162. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
O’Hare T, Walters DK, Stoffregen EP, et
al: In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825
against clinically relevant imatinib-resistant Abl kinase domain
mutants. Cancer Res. 65:4500–4505. 2005. View Article : Google Scholar
|
|
24
|
Shah NP, Tran C, Lee FY, Chen P, Norris D
and Sawyers CL: Overriding imatinib resistance with a novel ABL
kinase inhibitor. Science. 305:399–401. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
McCormack PL and Keam SJ: Dasatinib: a
review of its use in the treatment of chronic myeloid leukaemia and
Philadelphia chromosome-positive acute lymphoblastic leukaemia.
Drugs. 71:1771–1795. 2011. View Article : Google Scholar : PubMed/NCBI
|
